Skip to main content
. Author manuscript; available in PMC: 2016 Jun 15.
Published in final edited form as: J Surg Res. 2015 Mar 18;196(2):404–415. doi: 10.1016/j.jss.2015.03.026

Figure 5.

Figure 5

The effect of Paclitaxel (PTX) on hASCs adipogenic and osteogenic differentiation. A. Adipogenic differentiation. Oil Red O stain showed there were less stained lipid droplets in the adipogenic-induced hASCs treated with Paclitaxel as compared to control hASCs. B. Osteogenic differentiation. Alazarin red stain illustrated the calcium deposits seen in osteogenic-induced hASCs treated with and without Paclitaxel. C. Adipogenic markers, LPL and PPAR-γ, revealed reduced expression in Paclitaxel treated hASCs. (p=0.043, p=0.345). D. Osteogenic markers, alkaline phosphatase and osteopontin, revealed reduced expression in Paclitaxel treated hASCs. (p=0.043, p=0.345).